BackSangamo Therapeutics Overview

Sangamo Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for SGMO.

Quarterly EBIT

-$31.95M
↓ 7.82% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$125.66M
↓ 59.01% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin